Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.

Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, Ross BD.

Neoplasia. 2007 Dec;9(12):1003-11.


An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.

Lee KC, Sud S, Meyer CR, Moffat BA, Chenevert TL, Rehemtulla A, Pienta KJ, Ross BD.

Cancer Res. 2007 Apr 15;67(8):3524-8.


DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.

Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, Graves MJ, Stearn S, Lomas DJ, Griffiths JR, Neal D, Gnanapragasam VJ, Sala E.

Magn Reson Med. 2012 Mar;67(3):778-85. doi: 10.1002/mrm.23062. Epub 2011 Aug 29.


The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.

Onal C, Topkan E, Efe E, Yavuz M, Arslan G, Yavuz A.

Br J Radiol. 2009 Dec;82(984):1019-26. doi: 10.1259/bjr/65939531. Epub 2009 Jul 6.


Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.


Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Kobayashi M, Nukui A, Suzuki K, Kurokawa S, Morita T.

Int J Clin Oncol. 2011 Dec;16(6):630-6. doi: 10.1007/s10147-011-0232-4. Epub 2011 Apr 23.


Lack of energy, petechiae, elevated PSA level--Dx?

Subramaniam S, Choufani E, Manov A.

J Fam Pract. 2014 Oct;63(10):565-7. No abstract available.


The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.


EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.


Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.

Njiaju UO, Truica CI.

Clin Breast Cancer. 2010 Feb;10(1):E3-5. doi: 10.3816/CBC.2010.n.013.


Intermittent versus continuous androgen deprivation in prostate cancer.

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr.

N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299.


Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.


Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G.

Cancer Immunol Immunother. 2012 Jul;61(7):1137-47. doi: 10.1007/s00262-011-1193-1. Epub 2011 Dec 31.


Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

Soga N, Arima K, Sugimura Y.

Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.


Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations.

Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, John H, Binkert CA, Boesiger P, Gutzeit A.

Radiology. 2010 Nov;257(2):523-31. doi: 10.1148/radiol.10092469. Epub 2010 Sep 9.


Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.

Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V.

Clin Oncol (R Coll Radiol). 2013 Mar;25(3):190-6. doi: 10.1016/j.clon.2012.09.010. Epub 2012 Dec 17.


A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Amato R, Stepankiw M, Gonzales P.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1629-34. doi: 10.1007/s00280-013-2163-4. Epub 2013 Apr 21.


Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.

Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE, De Reijke TM, Kil PJ, Rea LA.

Eur Urol. 2003 Nov;44(5):505-11.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk